COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:

Key Record Dates Identifier: NCT02250326
Brief Title: Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer (abound2L+)

First Submitted : September 24, 2014
First Submitted that Met QC Criteria : September 24, 2014
First Posted : September 26, 2014 (Estimate)

Results First Submitted : July 13, 2018
Results First Submitted that Met QC Criteria : August 9, 2018
Results First Posted : August 10, 2018

Last Update Submitted that Met QC Criteria : December 19, 2019
Last Update Posted : December 30, 2019